,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2012', 'fs': 'Apr 2012', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEO72AP'}, 'Id': 'a0POZ00000XIEO72AP', 'Event_Date__c': '2012-04-03', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Apr 2012', 'Status_History__c': 'a132P000000Aq07QAC'}, 'change': None}]",Apr 2012,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': 'The Subcommittee noted that this pharmaceuticals is not subsidised in the community and is not widely used in DHB hospitals, but recommended that it be included in a national PML.', 'fs': 'The Subcommittee noted that this pharmaceuticals is not subsidised in the community and is not widely used in DHB hospitals, but recommended that it be included in a national PML.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended for funding with no priority', 'fs': 'Recommended for funding with no priority', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-various-group-minutes-2013-03.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-various-group-minutes-2013-03.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Apr 2012', 'fs': 'Apr 2012', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 3 April 2012.', 'fs': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 3 April 2012.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEO62AP'}, 'Id': 'a0POZ00000XIEO62AP', 'Event_Date__c': '2012-04-03', 'Event_Description__c': 'Clinical advice received from Hospital Pharmaceuticals Subcommittee at meeting Tuesday 3 April 2012.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-various-group-minutes-2013-03.pdf "" target=""_blank"">Hospital Pharmaceuticals Subcommittee minutes</a>', 'Outcome__c': 'Recommended for funding with no priority', 'Summary__c': 'The Subcommittee noted that this pharmaceuticals is not subsidised in the community and is not widely used in DHB hospitals, but recommended that it be included in a national PML.', 'Formatted_Date__c': 'Apr 2012', 'Status_History__c': 'a132P000000ApzxQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended for funding with no priority', 'fs': 'Recommended for funding with no priority', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2013', 'fs': 'Feb 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 February 2013.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 February 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEO82AP'}, 'Id': 'a0POZ00000XIEO82AP', 'Event_Date__c': '2013-02-14', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 14 February 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Recommended for funding with no priority', 'Formatted_Date__c': 'Feb 2013', 'Status_History__c': 'a132P000000AqJCQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended for funding with no priority', 'fs': 'Recommended for funding with no priority', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2013-03-22.pdf "" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2013-03-22.pdf "" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2013', 'fs': 'Mar 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 22 March 2013.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 22 March 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEOB2A5'}, 'Id': 'a0POZ00000XIEOB2A5', 'Event_Date__c': '2013-03-22', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 22 March 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-catsop-subcommittee-minutes-2013-03-22.pdf "" target=""_blank"">CaTSoP Subcommittee minutes</a>', 'Outcome__c': 'Recommended for funding with no priority', 'Formatted_Date__c': 'Mar 2013', 'Status_History__c': 'a132P000000AqLyQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Recommended for funding with no priority', 'fs': 'Recommended for funding with no priority', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2013', 'fs': 'Aug 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 30 August 2013.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 30 August 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEOD2A5'}, 'Id': 'a0POZ00000XIEOD2A5', 'Event_Date__c': '2013-08-30', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Friday 30 August 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Recommended for funding with no priority', 'Formatted_Date__c': 'Aug 2013', 'Status_History__c': 'a132P000000AqSPQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2017', 'fs': 'Jun 2017', 'change': None}, 'Event_Description': {'s': 'This application is on hold pending a supplier', 'fs': 'This application is on hold pending a supplier', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEOE2A5'}, 'Id': 'a0POZ00000XIEOE2A5', 'Event_Date__c': '2017-06-01', 'Event_Description__c': 'This application is on hold pending a supplier', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jun 2017', 'Status_History__c': 'a132P000000ArIVQA0'}, 'change': None}]",Apr 2012,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2013', 'fs': 'Mar 2013', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEOA2A5'}, 'Id': 'a0POZ00000XIEOA2A5', 'Event_Date__c': '2013-03-01', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Mar 2013', 'Status_History__c': 'a132P000000AqLWQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2023', 'fs': 'Jul 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEOF2A5'}, 'Id': 'a0POZ00000XIEOF2A5', 'Event_Date__c': '2023-07-04', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Jul 2023', 'Status_History__c': 'a132P000000F3eZQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2023', 'fs': 'Nov 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEOJ2A5'}, 'Id': 'a0POZ00000XIEOJ2A5', 'Event_Date__c': '2023-11-07', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Nov 2023', 'Status_History__c': 'a13OZ000004Xsx1YAC'}, 'change': None}, {'Summary': {'s': '<p>Carboxypeptidase G2 is required for emergency use in hospitals for high dose methotrexate toxicity. Concerns were highlighted about the time it can take to source this product from Australia when it is needed. We intend to seek further information relating to the need for this medicine and the potential options we have for progressing this application.</p><p><br></p>', 'fs': '<p>Carboxypeptidase G2 is required for emergency use in hospitals for high dose methotrexate toxicity. Concerns were highlighted about the time it can take to source this product from Australia when it is needed. We intend to seek further information relating to the need for this medicine and the potential options we have for progressing this application.</p><p><br></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2023', 'fs': 'Nov 2023', 'change': None}, 'Event_Description': {'s': 'No current New Zealand supplier.', 'fs': 'No current New Zealand supplier.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEOK2A5'}, 'Id': 'a0POZ00000XIEOK2A5', 'Event_Date__c': '2023-11-07', 'Event_Description__c': 'No current New Zealand supplier.', 'Stage__c': 'Under Assessment', 'Summary__c': '<p>Carboxypeptidase G2 is required for emergency use in hospitals for high dose methotrexate toxicity. Concerns were highlighted about the time it can take to source this product from Australia when it is needed. We intend to seek further information relating to the need for this medicine and the potential options we have for progressing this application.</p><p><br></p>', 'Formatted_Date__c': 'Nov 2023', 'Status_History__c': 'a13OZ000004XtI5YAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2026', 'fs': 'Feb 2026', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEOL2A5'}, 'Id': 'a0POZ00000XIEOL2A5', 'Event_Date__c': '2026-02-03', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2026', 'Status_History__c': 'a13OZ00000ZazaJYAR'}, 'change': None}]",Mar 2013,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmacâ€™s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2023', 'fs': 'Jul 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEOG2A5'}, 'Id': 'a0POZ00000XIEOG2A5', 'Event_Date__c': '2023-07-06', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jul 2023', 'Status_History__c': 'a132P000000FC9DQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2026', 'fs': 'Feb 2026', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEOM2A5'}, 'Id': 'a0POZ00000XIEOM2A5', 'Event_Date__c': '2026-02-04', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Feb 2026', 'Status_History__c': 'a13OZ00000ZegB0YAJ'}, 'change': None}]",Jul 2023,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2013', 'fs': 'Feb 2013', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEO92AP'}, 'Id': 'a0POZ00000XIEO92AP', 'Event_Date__c': '2013-02-25', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Formatted_Date__c': 'Feb 2013', 'Status_History__c': 'a132P000000AqKuQAK'}, 'change': None}, {'Summary': {'s': '<p>We are proposing to decline this application as we\xa0understand there is currently no Medsafe approved product available in New Zealand. We are not aware of any supplier willing to pursue Medsafe registration.</p>', 'fs': '<p>We are proposing to decline this application as we\xa0understand there is currently no Medsafe approved product available in New Zealand. We are not aware of any supplier willing to pursue Medsafe registration.</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-08-02-proposal-to-decline-inactive-funding-applications"" target=""_blank"">Consultation notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-08-02-proposal-to-decline-inactive-funding-applications"" target=""_blank"">Consultation notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2023', 'fs': 'Aug 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEOH2A5'}, 'Id': 'a0POZ00000XIEOH2A5', 'Event_Date__c': '2023-08-01', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-08-02-proposal-to-decline-inactive-funding-applications"" target=""_blank"">Consultation notification</a></p>', 'Summary__c': '<p>We are proposing to decline this application as we\xa0understand there is currently no Medsafe approved product available in New Zealand. We are not aware of any supplier willing to pursue Medsafe registration.</p>', 'Formatted_Date__c': 'Aug 2023', 'Status_History__c': 'a13OZ0000019ajkYAA'}, 'change': None}]",Feb 2013,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': 'Proposes not to list glucarpidase (carboxypeptidase G2) in Part II of Section H at this time, but notes that this would not prevent it from being considered for inclusion at a later date.', 'fs': 'Proposes not to list glucarpidase (carboxypeptidase G2) in Part II of Section H at this time, but notes that this would not prevent it from being considered for inclusion at a later date.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2013', 'fs': 'Mar 2013', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEOC2A5'}, 'Id': 'a0POZ00000XIEOC2A5', 'Event_Date__c': '2013-03-28', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Summary__c': 'Proposes not to list glucarpidase (carboxypeptidase G2) in Part II of Section H at this time, but notes that this would not prevent it from being considered for inclusion at a later date.', 'Formatted_Date__c': 'Mar 2013', 'Status_History__c': 'a132P000000AqMwQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-11-07-decision-to-decline-inactive-applications-for-the-funding-of-some-medicines"" target=""_blank"">Decision notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-11-07-decision-to-decline-inactive-applications-for-the-funding-of-some-medicines"" target=""_blank"">Decision notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Sep 2023', 'fs': 'Sep 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000XIEOI2A5'}, 'Id': 'a0POZ00000XIEOI2A5', 'Event_Date__c': '2023-09-01', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-11-07-decision-to-decline-inactive-applications-for-the-funding-of-some-medicines"" target=""_blank"">Decision notification</a></p>', 'Formatted_Date__c': 'Sep 2023', 'Status_History__c': 'a13OZ000004XyW9YAK'}, 'change': None}]",Mar 2013,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
